Antitumor immunity induced after α irradiation

Neoplasia (United States)

Volumn 16, Issue 4, 2014, Pages 319-328

  Gorin, Jean Baptiste ^a,b,c   Ménager, Jérémie ^a,b,c   Gouard, Sébastien ^a,b,c   Maurel, Catherine ^a,b,c   Guilloux, Yannick ^a,b,c   Faivre Chauvet, Alain ^a,b,c,d   Morgenstern, Alfred ^f   Bruchertseiferf, Frank ^g   Chérel, Michel ^a,b,c,e   Davodeau, François ^a,b,c   Gaschet, Joëlle ^a,b,c  

^a Team 12   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UMR INSERM U892 CNRS 6299   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f JOINT RESEARCH CENTRE   (Italy)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BISMUTH 213; CD40 ANTIGEN; CD86 ANTIGEN; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR ANTIGEN; CANCER VACCINE;

ADAPTIVE IMMUNITY; ADENOCARCINOMA CELL LINE; ALPHA IRRADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IN VIVO STUDY; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; ALPHA RADIATION; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOMODULATION; MORTALITY; NEOPLASMS; PATHOLOGY; RADIATION RESPONSE; T LYMPHOCYTE SUBPOPULATION; THERAPEUTIC USE; TUMOR CELL LINE; TUMOR VOLUME;

ALPHA PARTICLES; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; IMMUNOMODULATION; MICE; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84903987614     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.04.002     Document Type: Article

References (47)

1. Goldberg Z and Lehnert BE (2002). Radiation-induced effects in unirradiated cells: A review and implications in cancer. Int J Oncol 21, 337-349.
2. Morgan WF (2003). Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation? Oncogene 22, 7094-7099.
3. Mothersill C and Seymour CB (2004). Radiation-induced bystander effects- implications for cancer. Nat Rev Cancer 4, 158-164.
4. Barbet J, Bardiès M, Bourgeois M, Chatal JF, Chérel M, Davodeau F, Faivre-Chauvet A, Gestin JF, and Kraeber-Bodéré F (2012). Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol 907, 681-697.
5. Sharkey RM and Goldenberg DM (2011). Cancer radioimmunotherapy. Immunotherapy 3, 349-370.
6. 2 delay: a period of cell recovery. Radiat Res 89, 298-308.
7. 2 cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 11, 639-648.
8. Søyland C andHassfjell SP (2000). Survival of human lung epithelial cells following in vitro α-particle irradiation with absolute determination of the number of α-particle traversals of individual cells. Int J Radiat Biol 76, 1315-1322.
9. Humm JL and Cobb LM (1990). Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31, 75-83.
10. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, and Akabani G, et al (2010). MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med 51, 311-328.
11. Seideman JH, Stancevic B, Rotolo JA,McDevittMR, Howell RW, Kolesnick RN, and Scheinberg DA (2011). Alpha particles induce apoptosis through the sphingomyelin pathway. Radiat Res 176, 434-446.
12. Friesen C, Roscher M, Hormann I, Leib O, Marx S, Moreno J, and Miltner E (2013). Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur J Cancer 49, 2542-2554.
13. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, Davodeau F, and Cherel M (2005). Mechanisms of cell sensitization to α radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 11, 7047s-7052s.
14. 2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe. Mol Cancer Ther 6, 2346-2359.
15. BoydM, Ross SC, Dorrens J, Fullerton NE, Tan KW, ZalutskyMR, and Mairs RJ (2006). Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and auger electron-emitting radionuclides. J NuclMed 47, 1007-1015.
16. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, and Guha C (1999). Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 59, 6028-6032.
17. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, and Formenti SC (2004). Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58, 862-870.
18. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, and Formenti SC (2012). The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2, 88.
19. Formenti SC and Demaria S (2012). Combining radiotherapy and Cancer Immunotherapy: a Paradigm Shift. J Natl Cancer Inst 1-10.
20. Cameron RB, Spiess PJ, and Rosenberg SA (1990). Synergistic antitumor activity of Tumor-Infiltrating Lymphocytes, Interleukin-2 and local tumor irradiation. J Exp Med 171, 249-263.
21. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, and Hodge JW (2008). Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 57, 1173-1183.
22. NikulaTK,CurcioMJ, BrechbielMW, GansowOA, Finn RD, and ScheinbergDA (1995). A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 22, 387-390.
23. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, and Mulligan RC (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90, 3539-3543.
24. Delemarre FG, Hoogeveen PG, De Haan-Meulman M, Simons PJ, and Drexhage HA (2001). Homotypic cluster formation of dendritic cells, a close correlate of their state of maturation. Defects in the biobreeding diabetes-prone rat. J Leukoc Biol 69, 373-380.
25. Matzinger P (2002). The danger model: a renewed sense of self. Science 296, 301-305.
26. Tang D, Kang R, Coyne CB, Zeh HJ, and LotzeM(2012). PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 249, 158-175.
27. Nace G, Evankovich J, Eid R, and Tsung A (2012). Dendritic cells and damageassociated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun 4, 6-15.
28. Kroemer G, Galluzzi L, Kepp O, and Zitvogel L (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol 31, 51-72.
29. Gabrilovich D (2004). Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat Rev Immunol 4, 941-952.
30. Bianchi ME (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81, 1-5.
31. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, and Agostinis P (2010). Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805, 53-71.
32. Basu S, Binder RJ, Ramalingam T, and Srivastava PK (2001). CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14, 303-313.
33. Andersson U and Tracey KJ (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29, 139-162.
34. Suzuki Y, Mimura K, Yoshimoto Y,Watanabe M, Ohkubo Y, Izawa S,Murata K, Fujii H, Nakano T, and Kono K (2012). Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72, 3967-3976.
35. Chung H, Lee SG, Kim H, Hong D, Chung J, Stroncek D, and Lim JB (2009). Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7, 38.
36. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, CaoM, Liu DM, and Huang YR (2012). Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 106, 57-61.
37. Riuzzi F, Sorci G, and Donato R (2006). The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 281, 8242-8253.
38. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, and YasuiW(2002). Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196, 163-170.
39. Sasahira T, Akama Y, Fujii K, and Kuniyasu H (2005). Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446, 411-415.
40. van Beijnum JR, Buurman WA, and Griffioen AW (2008). Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11, 91-99.
41. Campana L, Bosurgi L, and Rovere-Querini P (2008). HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 20, 518-523.
42. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, and Raeli L, et al (2012). Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209, 1519-1528.
43. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, and Saulnier P, et al (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-1059.
44. Garnett CT1, Palena C, Chakraborty M, Tsang KY, Schlom J, and Hodge JW (2004). Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64, 7985-7994.
45. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, and Hodge JW (2004). External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64, 4328-4337.
46. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, and Neijssen J, et al (2006). Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203, 1259-1271.
47. Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, and Hodge JW (2008). The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14, 4241-4249.